人福医药：HW241045片获药物临床试验批准

Core Viewpoint - The company has received approval for clinical trials of HW241045 tablets, which are intended for the treatment of idiopathic pulmonary fibrosis, marking a significant development as there are currently no approved drugs targeting the same pathway globally [1] Group 1 - The company's wholly-owned subsidiary, Wuhan Renfu Innovative Drug Research Center Co., Ltd., has obtained the Drug Clinical Trial Approval Notice from the National Medical Products Administration [1] - HW241045 tablets are specifically designed for the treatment of idiopathic pulmonary fibrosis [1] - There are no other drugs approved globally that target the same pathway as HW241045 [1]